Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

By Cavalli-Björkman Nina   Ösby Eva   Lundin Jeanette   Kalin Mats   Österborg Anders   Gruber Astrid  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 277-280

Humana Press, Inc

Access to resources Recommend Favorite

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

By Lundin Jeanette   Karlsson Claes   Celsing Fredrik  

Medical Oncology, Vol. 23, Iss. 1, 2006-03 ,pp. : 137-139

Humana Press, Inc

Access to resources Recommend Favorite

Alemtuzumab in chronic lymphocytic leukemia

By James Danelle F   Kipps Thomas J  

Future Oncology, Vol. 3, Iss. 1, 2007-02 ,pp. : 29-42

Future Medicine

Access to resources Recommend Favorite

B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case–control study in Greece

By Dalamaga Maria  

Cancer Causes and Control, Vol. 21, Iss. 9, 2010-09 ,pp. : 1451-1459

Springer Publishing Company

Access to resources Recommend Favorite

Eradication of Minimal Residual Disease with Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients: The Need for a Standard Method of Detection and the Potential Impact of Bone Marrow Clearance on Disease Outcome

By Montillo Marco   Schinkoethe Timo   Elter Thomas  

Cancer Investigation, Vol. 23, Iss. 6, 2005-09 ,pp. : 488-496

Informa Healthcare

Access to resources Recommend Favorite